Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPGS | Q05932 | 3/20 | 0.86 |
| ▸ | DHFR | P00374 | 3/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.86 |
| ▸ | TLR4 | O00206 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | TP53 | P04637 | 1/20 | 0.86 |
| ▸ | TYMS | P04818 | 1/20 | 0.86 |
| ▸ | GLA | P06280 | 1/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 1/20 | 0.86 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.86 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.86 |
| ▸ | HPGD | P15428 | 1/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.86 |
| ▸ | GART | P22102 | 1/20 | 0.86 |
| ▸ | APEX1 | P27695 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methopterine SCHEMBL159228 | 1.00 | FPGS (0.86) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methopterine SCHEMBL10658766 | 0.99 | FPGS (0.84) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL9736207 | 0.97 | DHFR (0.92) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL2301949 | 0.92 | DHFR (1.00) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3712 | 0.92 | DHFR (1.00) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL16013534 | 0.92 | DHFR (1.00) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL171251 | 0.92 | DHFR (1.00) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL20548444 | 0.92 | DHFR (1.00) | FPGSDHFRKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3711 | 0.92 | DHFR (1.00) | FPGSDHFRKDM4ETLR4MEN1 | |
| SCHEMBL13524540 | 0.92 | DHFR (0.87) | FPGSDHFRKDM4ETLR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2552931-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | GILEAD PHARMASSET LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752422-A1 | Stereoselective synthesis of phosphorus containing actives | Gilead Pharmasset LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2011123668-A2 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-6689756-B2 | VIA CATHETER COMPRISING ANTIMICROBIAL AGENT AND SECOND CATHETER FOR WITHDRAWING FLUID; FOR TREATING INFECTION OR NEOPLASM OF CEREBROSPINAL TISSUE | INTEGRA LIFESCIENCES CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20030022879-A1 | Treatment of neurological disease | INTEGRA LIFESCIENCES CORPORATION | 2003-01-30 | — | — | US | disclosed |
| WO-2002069893-A2 | TREATMENT OF NEUROLOGICAL DISEASE | NEURON THERAPEUTICS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | FPGS 790/4885DHFR 1717/4885KDM4E 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.